Changes in microtubular tau protein after estrogen in a cultured human neuroblastoma cell line

Lew, G.M.

doi:10.1016/0306-3623(93)90423-u

Cited by 11 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A positive correlation between TAU expression and the receptors for estrogen and progesterone (PR) expression was confirmed in multiple studies, in particular for low grade, ER/PR-positive, and human epidermal growth factor receptor 2 (HER2)-negative cancers [96][97][98][104][105][106]]. An inducible imperfect estrogen response element was identified upstream of the MAPT promoter [106][107][108][109][110][111][112], which is consistent with the endocrine sensitivity of TAU-and ER-positive In breast cancer, higher TAU protein expression is associated to a better outcome and survival independently to the therapy [96][97][98]104,105]. However, TAU level did not correlate with tumor size or nodal status or patient age.…”

Section: Tau As a Prognostic Marker In Cancermentioning

confidence: 98%

“…A positive correlation between TAU expression and the receptors for estrogen and progesterone (PR) expression was confirmed in multiple studies, in particular for low grade, ER/PR-positive, and human epidermal growth factor receptor 2 (HER2)-negative cancers [96][97][98][104][105][106]]. An inducible imperfect estrogen response element was identified upstream of the MAPT promoter [106][107][108][109][110][111][112], which is consistent with the endocrine sensitivity of TAU-and ER-positive tumors [98]. Among a panel of breast cancer cell lines with different levels of TAU mRNA and TAU isoforms, down-regulation of ER expression and the presence of ER inhibitors affected TAU expression in a cell-specific manner [85,108,113,114].…”

Section: Tau As a Prognostic Marker In Cancermentioning

confidence: 98%

See 1 more Smart Citation

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

Papin

Paganetti

2020

Brain Sciences

View full text Add to dashboard Cite

Neurodegenerative disorders and cancer may appear unrelated illnesses. Yet, epidemiologic studies indicate an inverse correlation between their respective incidences for specific cancers. Possibly explaining these findings, increasing evidence indicates that common molecular pathways are involved, often in opposite manner, in the pathogenesis of both disease families. Genetic mutations in the MAPT gene encoding for TAU protein cause an inherited form of frontotemporal dementia, a neurodegenerative disorder, but also increase the risk of developing cancer. Assigning TAU at the interface between cancer and neurodegenerative disorders, two major aging-linked disease families, offers a possible clue for the epidemiological observation inversely correlating these human illnesses. In addition, the expression level of TAU is recognized as a prognostic marker for cancer, as well as a modifier of cancer resistance to chemotherapy. Because of its microtubule-binding properties, TAU may interfere with the mechanism of action of taxanes, a class of chemotherapeutic drugs designed to stabilize the microtubule network and impair cell division. Indeed, a low TAU expression is associated to a better response to taxanes. Although TAU main binding partners are microtubules, TAU is able to relocate to subcellular sites devoid of microtubules and is also able to bind to cancer-linked proteins, suggesting a role of TAU in modulating microtubule-independent cellular pathways associated to oncogenesis. This concept is strengthened by experimental evidence linking TAU to P53 signaling, DNA stability and protection, processes that protect against cancer. This review aims at collecting literature data supporting the association between TAU and cancer. We will first summarize the evidence linking neurodegenerative disorders and cancer, then published data supporting a role of TAU as a modifier of the efficacy of chemotherapies and of the oncogenic process. We will finish by addressing from a mechanistic point of view the role of TAU in de-regulating critical cancer pathways, including the interaction of TAU with cancer-associated proteins.

show abstract

Section: Tau As a Prognostic Marker In Cancermentioning

confidence: 98%

“…A positive correlation between TAU expression and the receptors for estrogen and progesterone (PR) expression was confirmed in multiple studies, in particular for low grade, ER/PR-positive, and human epidermal growth factor receptor 2 (HER2)-negative cancers [96][97][98][104][105][106]]. An inducible imperfect estrogen response element was identified upstream of the MAPT promoter [106][107][108][109][110][111][112], which is consistent with the endocrine sensitivity of TAU-and ER-positive tumors [98]. Among a panel of breast cancer cell lines with different levels of TAU mRNA and TAU isoforms, down-regulation of ER expression and the presence of ER inhibitors affected TAU expression in a cell-specific manner [85,108,113,114].…”

Section: Tau As a Prognostic Marker In Cancermentioning

confidence: 98%

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

Papin

Paganetti

2020

Brain Sciences

View full text Add to dashboard Cite

show abstract

“…Estrogen is protective against neuronal death (25)(26)(27)(28). E 2 induces cytosolic Tau expression during 24-h treatment of human SH-SY5Y neuroblastoma cells (56), induces differentiation of a neuronal cell line (57), but cannot change Tau expression in rat brains (58). In this study, we determined that during a short term treatment for less than 1 h, E 2 enhanced the binding of WOX1 with phosphorylated Tau at Thr 212 /Ser 214 and Ser 515 /Ser 516 and GSK-3␤ with Tau and WOX1 in L929 cells.…”

Section: Discussionmentioning

confidence: 99%

Down-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro

Sze¹,

Su²,

Pugazhenthi

et al. 2004

Journal of Biological Chemistry

114

212

View full text Add to dashboard Cite

“…Because the definition of the mechanisms underlying the regulation of neurosteroid synthesis is crucial for understanding the role of neurosteroids in physiological and altered CNS functions, we used the human neuroblastoma SH-SY5Y cell line as a model system to study pregnenolone synthesis and its regulation by cytoskeleton. Several lines of evidence indicate this neuroblastoma cell line as an appropriate model to our purpose: 1) SH-SY5Y cells display steroidogenic ability in that testosterone and progesterone may be converted to 5␣-reduced derivatives and further metabolites by 5␣-reductase and 3␣hydroxysteroid dehydrogenase enzymes (Melcangi et al, 1993); 2) SH-SY5Y cells are responsive to steroid treat-ments: estrogens and progesterone have been reported to increase prostaglandin E1-induced cAMP accumulation (Ratka et al, 1991), to alter the nicotinic acetylcholine receptor function (Ke and Lukas, 1996) and to change the metabolism of microtubule tau protein (Lew, 1993); 3) this human neuroblastoma cell line is able to synthesize apolipoprotein E that regulates cholesterol homeostasis (Dupont-Wallois et al, 1997); and 4) phenotypic changes of SH-SY5Y cells associated with differentiation may differ greatly depending upon the agent used (Påhlman et al, 1984). Through immunocytochemical and biochemical approaches, we here demonstrate that cytP450scc is present and operative in cells undifferentiated and differentiated with retinoic acid (RA) or phorbol ester 12-Otetradecanoylphorbol-13-acetate (TPA).…”

mentioning

confidence: 99%

Human neuroblastoma SH-SY5Y cell line: Neurosteroid-producing cell line relying on cytoskeletal organization

et al. 2000

View full text Add to dashboard Cite

Pregnenolone, the precursor of all steroids, is synthesized by CNS structures. The synthesis requires an obligatory step involving cholesterol transport to mitochondrial cytochrome P450-cholesterol side chain cleavage (cytP450scc), although the underlying mechanism(s) are still mostly unknown. We used the human neuroblastoma SH-SY5Y cell line to investigate cytP450scc expression and activity and to establish a role of cytoskeleton in pregnenolone synthesis. Immunocytochemical and biochemical approaches revealed that undifferentiated as well as differentiated cells either by retinoic acid (RA) or phorbol ester 12-O-tetradecanoylphorbol-13-acetate (TPA), possess cytP450scc and rapidly synthesize pregnenolone in the presence of a NADPH-generating system. The newly neurosteroid formation by SH-SY5Y cells was increased by 22R-hydroxycholesterol and blocked by the cytP450scc inhibitor, aminoglutethimide. When trilostane was used to inhibit 3beta-hydroxysteroid dehydrogenase catalyzing pregnenolone conversion into progesterone, a higher pregnenolone accumulation occurred in TPA-differentiated cells than in RA-differentiated ones. Although SU 10603, a blocker of 17alpha-hydroxylase/c17,20-lyase enzyme involved in DHEA formation from pregnenolone, gave rise to an elevated neurosteroid content only in RA-differentiated cells. No difference in pregnenolone levels was found in undifferentiated cells treated with each inhibitor. Thus, differentiation seems to promote pregnenolone-metabolizing enzyme activities that may vary upon phenotypic changes induced by RA or TPA. Treatments of differentiated cells with the microtubule-depolymerizing drug colchicine and the actin microfilament-altering agent cytochalasin D decreased pregnenolone synthesis without affecting cell viability or cytP450scc amount. Addition of the cell-permeant cholesterol analogue 22R-hydroxycholesterol known to elude cholesterol transport systems induced pregnenolone synthesis, however, indicating that perturbations in cytoskeleton likely affect endogenous cholesterol transport. The relevance of this finding may rest on the observed involvement of cytoskeletal organization in such events as neuronal plasticity, cognitive function and also neurodegenerative disorders in which neurosteroids have been shown to have a part.

show abstract

Changes in microtubular tau protein after estrogen in a cultured human neuroblastoma cell line

Cited by 11 publications

References 17 publications

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

Emerging Evidences for an Implication of the Neurodegeneration-Associated Protein TAU in Cancer

Down-regulation of WW Domain-containing Oxidoreductase Induces Tau Phosphorylation in Vitro

Human neuroblastoma SH-SY5Y cell line: Neurosteroid-producing cell line relying on cytoskeletal organization

Contact Info

Product

Resources

About